You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
李彥宏旗下百圖生科獲上億美元A輪融資 百度(09888.HK)跟投
生物計算創新藥物研發平臺百圖生科,近日完成由GGV紀源資本領投的上億美元A輪融資,百度(09888.HK)、君聯資本、藍馳創投、真知資本及襄禾資本等跟投,創始人兼百度董事長李彥宏繼續追加投資,預期融資所得將主要用於技術研發及引進人才。

百圖生科定位爲由生物計算引擎驅動的創新藥物研發平臺型企業,李彥宏於2020年11月牽頭創立並出任董事長,主要通過先進計算和生物技術,繪製關於疾病靶點和藥物設計的圖譜,實現Global First-in-class原創藥物的研發,未來料將主要聚焦在腫瘤、自身免疫性疾病、纖維化疾病的免疫機理研究領域。

此輪融資過後,百圖生科計劃進一步加大其生物計算引擎的建設力度,在多組學技術、高通量實驗技術、蛋白質計算技術、高性能生物計算技術等領域繼續研發,加大人才的引進力度,並推動其首批藥物研發管線達到新階段。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account